170692

ADAMTS18

ADAMTS21|KNO2;ADAM metallopeptidase with thrombospondin type 1 motif, 18;ADAMTS18;ADAM metallopeptidase with thrombospondin type 1 motif, 18

A disintegrin and metalloproteinase with thrombospondin motifs 18|a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 18|a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 21|d

16q23

protein-coding

Count: 1; Generif

tumor suppressor genes (TSGs) often locate at chromosomal regions with frequent deletions in tumors. Loss of 16q23 occurs frequently in multiple tumors, indicating the presence of critical TSGs at this locus, such as the well-studied WWOX. Herein, we found that ADAMTS18, located next to WWOX, was significantly downregulated in multiple carcinoma cell lines. No deletion of ADAMTS18 was detected with multiplex differential DNA-PCR or high-resolution 1-Mb array-based comparative genomic hybridization (CGH) analysis. Instead, methylation of the ADAMTS18 promoter CpG Island was frequently detected with methylation-specific PCR and bisulfite genome sequencing in multiple carcinoma cell lines and primary carcinomas, but not in any nontumor cell line and normal epithelial tissue. Both pharmacological and genetic demethylation dramatically induced the ADAMTS18 expression, indicating that CpG methylation directly contributes to the tumor-specific silencing of ADAMTS18. Ectopic ADAMTS18 expression led to significant inhibition of both anchorage-dependent and -independent growth of carcinoma cells lacking the expression. Thus, through functional epigenetics, we identified ADAMTS18 as a novel functional tumor suppressor, being frequently inactivated epigenetically in multiple carcinomas.